Charles River Announces Agreement with Singapore General Hospital
February 25 2025 - 7:00AM
Business Wire
Charles River to provide master cell banking
and NGS testing services for cord blood derived allogeneic CAR-T
cells
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced an agreement with Singapore General Hospital (SGH) to
provide Current Good Manufacturing Practice (CGMP) -compliant
master cell banking (MCB) and next-generation sequencing
(NGS)-based services for use in cell line characterization. SGH
will use cord blood to derive and manufacture allogeneic chimeric
antigen receptor (CAR) T-cells which will be used to treat patients
with cancer.
“We are thrilled to leverage our cell line characterization
services and comprehensive NGS testing approach to support SGH as
they work to develop novel therapeutics for cancer patients,” said
Kerstin Dolph, Corporate Senior Vice President, Global
Manufacturing, Charles River. “According to the World Health
Organization, 1 in 5 individuals will develop cancer in their
lifetime, so utilizing our decades of experience to help advance
novel cancer research is aligned with our corporate values and
goals.”
SGH will leverage Charles River’s CGMP MCB services for SGH’s
critical starting material for its cord blood-derived allogeneic
CAR T-cells and NGS-based testing services for cell line
characterization services for its upcoming Phase I clinical
trials.
Next Generation Sequencing NGS is revolutionizing the way
advanced therapeutics are characterized and tested to ensure
high-quality products are delivered to patients. NGS has
transformed the genetic analysis and pathogen detection landscape
with its high throughput, scalability, and speed.
“As part of the cell characterization agreement, SGH will have
access to Charles River’s CGMP NGS services, significantly
increasing the capability of detecting viral contaminations in cell
banks, providing a faster, more efficient, and reliable testing
option compared to animal-based testing, and addressing their
dynamic needs,” continued Dolph.
Charles River’s CGMP NGS testing services accelerate development
timelines without compromising safety and meets regulatory
requirements for accuracy, reliability, and compliance with GMP,
FDA, EMA, and ICH Q5A and Q5B.
Biologics Testing Solutions Backed by decades of cell
banking and cell line characterization expertise, Charles River’s
full range of CGMP-compliant cell bank production and storage
services include 9 CGMP-compliant ISO-6 cleanroom suites, 8-10 week
cell bank completion to release, and over 2,000 cell and viral
banks produced supporting client programs from research and
development through commercial manufacturing.
About Singapore General Hospital Singapore General
Hospital, established in 1821, is the largest tertiary hospital in
Singapore and ranked among the world's best. It provides the most
comprehensive patient-centered care with over 50 clinical
specialties on its campus. As an Academic Medical Centre, it takes
pride in training healthcare professionals and conducting cutting
edge research to meet evolving needs of the nation as well as the
region. Driven by a strong sense of purpose, SGH is committed to
give its best to heal and bring hope, as it has for over 200 years.
For more information, please visit www.sgh.com.sg.
About Charles River Charles River provides essential
products and services to help pharmaceutical and biotechnology
companies, government agencies and leading academic institutions
around the globe accelerate their research and drug development
efforts. Our dedicated employees are focused on providing clients
with exactly what they need to improve and expedite the discovery,
early-stage development and safe manufacture of new therapies for
the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250225498319/en/
Charles River Investor Contact: Todd Spencer Corporate
Vice President, Investor Relations 781.222.6455
todd.spencer@crl.com
Charles River Media Contact: Amy Cianciaruso Corporate
Vice President, Chief Communications Officer 781.222.6168
amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Jan 2025 to Feb 2025
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Feb 2024 to Feb 2025